After coming off a slow third quarter, where 10 biopharma companies completed their IPOs in the U.S., collectively raising just over $1 billion, the U.S. IPO market has picked up once again. Already, at the halfway point in the fourth quarter, nine biopharma companies have graduated to the public ranks raising a total of almost $1 billion. Read More
